Becton Dickinson Reports Q4 & FY2026 Financial Results

Event Overview

On November 5, 2026, Becton, Dickinson and Company (BD) filed an 8-K under Item 2.02 reporting financial results for its fourth quarter and fiscal year ended September 30, 2026.

Key Financial Highlights

• Q4 FY2026 Revenue: Reached $5.274 billion, up 5.4% as reported (5.6% foreign currency-neutral) compared to $5.005 billion in Q4 FY2025.
• Q4 Diluted EPS: GAAP diluted EPS expanded to $2.52 from $1.20 in the prior-year period. Adjusted diluted EPS rose 27.3% to $4.15 compared to $3.26 in Q4 FY2025.
• Full-Year FY2026 Performance:
  • Revenue totaled $19.5 billion, up 4.9% reported (3.9% FXN).
  • GAAP diluted EPS was $5.06; Adjusted diluted EPS stood at $12.70.
  • Operating cash flow from continuing operations grew 30.0% to $3.6 billion, while free cash flow jumped 42.5% to $2.9 billion.
• Segment Results (Q4 FY2026 Revenue):
  • Medical Essentials: $1.786 billion (+5.9% YoY)
  • Interventional: $1.472 billion (+7.7% YoY reported)
  • Connected Care: $1.269 billion (+1.6% YoY)
  • BioPharma Systems: $748 million (+6.5% YoY)

Strategic and Operational Milestones

• Portfolio Realignment: Completed the spin-off and merger of the former Biosciences and Diagnostic Solutions (Life Sciences) business with Waters Corporation in February 2026; past periods have been recast into continuing operations.
• Domestic Manufacturing Commitment: Announced a multi-year partnership with the U.S. government involving an intended $19 billion investment in U.S. supply chains and manufacturing, with tariff relief under Section 232 subject to milestone achievements.